Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
UBS
Moodys
Queensland Health
US Army
Boehringer Ingelheim
Fuji
Teva
Dow
Accenture

Generated: October 17, 2017

DrugPatentWatch Database Preview

GLUCOTROL XL Drug Profile

« Back to Dashboard

What is the patent landscape for Glucotrol Xl, and when can generic versions of Glucotrol Xl launch?

Glucotrol Xl is a drug marketed by Pfizer and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-four patent family members in nineteen countries.

The generic ingredient in GLUCOTROL XL is glipizide. There are eighteen drug master file entries for this compound. Fifty-six suppliers are listed for this compound. Additional details are available on the glipizide profile page.

Summary for Tradename: GLUCOTROL XL

US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list6
Bulk Api Vendors: see list72
Clinical Trials: see list5
Patent Applications: see list5,581
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:GLUCOTROL XL at DailyMed

Pharmacology for Tradename: GLUCOTROL XL

Ingredient-typeSulfonylurea Compounds
Drug ClassSulfonylurea
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer
GLUCOTROL XL
glipizide
TABLET, EXTENDED RELEASE;ORAL020329-003Aug 10, 1999ABRXYesNo► Subscribe► Subscribe ► Subscribe
Pfizer
GLUCOTROL XL
glipizide
TABLET, EXTENDED RELEASE;ORAL020329-001Apr 26, 1994ABRXYesNo► Subscribe► Subscribe ► Subscribe
Pfizer
GLUCOTROL XL
glipizide
TABLET, EXTENDED RELEASE;ORAL020329-002Apr 26, 1994ABRXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: GLUCOTROL XL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer
GLUCOTROL XL
glipizide
TABLET, EXTENDED RELEASE;ORAL020329-003Aug 10, 1999► Subscribe► Subscribe
Pfizer
GLUCOTROL XL
glipizide
TABLET, EXTENDED RELEASE;ORAL020329-002Apr 26, 1994► Subscribe► Subscribe
Pfizer
GLUCOTROL XL
glipizide
TABLET, EXTENDED RELEASE;ORAL020329-002Apr 26, 1994► Subscribe► Subscribe
Pfizer
GLUCOTROL XL
glipizide
TABLET, EXTENDED RELEASE;ORAL020329-001Apr 26, 1994► Subscribe► Subscribe
Pfizer
GLUCOTROL XL
glipizide
TABLET, EXTENDED RELEASE;ORAL020329-002Apr 26, 1994► Subscribe► Subscribe
Pfizer
GLUCOTROL XL
glipizide
TABLET, EXTENDED RELEASE;ORAL020329-003Aug 10, 1999► Subscribe► Subscribe
Pfizer
GLUCOTROL XL
glipizide
TABLET, EXTENDED RELEASE;ORAL020329-001Apr 26, 1994► Subscribe► Subscribe
Pfizer
GLUCOTROL XL
glipizide
TABLET, EXTENDED RELEASE;ORAL020329-002Apr 26, 1994► Subscribe► Subscribe
Pfizer
GLUCOTROL XL
glipizide
TABLET, EXTENDED RELEASE;ORAL020329-002Apr 26, 1994► Subscribe► Subscribe
Pfizer
GLUCOTROL XL
glipizide
TABLET, EXTENDED RELEASE;ORAL020329-001Apr 26, 1994► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: GLUCOTROL XL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,361,795 Method for lowering blood glucose► Subscribe
5,024,843 Oral hypoglycemic glipizide granulation► Subscribe
5,545,413 Dosage form for administering oral hypoglycemic glipizide► Subscribe
5,591,454 Method for lowering blood glucose► Subscribe
5,091,190 Delivery system for administration blood-glucose lowering drug► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: GLUCOTROL XL

Country Document Number Estimated Expiration
Greece1000932► Subscribe
Australia6417590► Subscribe
JapanH05500222► Subscribe
Australia632859► Subscribe
Norway920740► Subscribe
New Zealand235127► Subscribe
Germany69003392► Subscribe
Denmark0490991► Subscribe
Greece900100659► Subscribe
Austria94393► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
QuintilesIMS
AstraZeneca
Harvard Business School
Chubb
Cipla
Johnson and Johnson
Cerilliant
Federal Trade Commission
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot